Trials / Terminated
TerminatedNCT05000346
Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms
A Randomized, Double-blind, Placebo-controlled, Parallel, Trial to Determine the Safety and Efficacy of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Aquilon Pharmaceuticals S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Double-blind parallel trial to assess the efficacy and safety of inhaled AQ001S in the management of acute COVID-19 symptoms compared.
Detailed description
A randomized, double-blind, placebo-controlled, parallel clinical trial to determine the safety and efficacy of inhaled AQ001S in the management of acute COVID-19 symptoms in adult patients (≥ 18 years old) who are admitted to hospital due to the severity of his/her confirmed or suspected COVID-19 disease. The patient will be treated for 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug, inhalation | Solution administered by inhalation |
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2022-12-21
- Completion
- 2022-12-21
- First posted
- 2021-08-11
- Last updated
- 2023-01-06
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05000346. Inclusion in this directory is not an endorsement.